Previous close | 186.70 |
Open | 189.40 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 189.40 - 189.40 |
52-week range | 177.60 - 304.00 |
Volume | |
Avg. volume | 4 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 23 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Biogen ( NASDAQ:BIIB ) First Quarter 2024 Results Key Financial Results Revenue: US$2.29b (down 7.0% from 1Q 2023). Net...
It's been a good week for Biogen Inc. ( NASDAQ:BIIB ) shareholders, because the company has just released its latest...
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.